Canada: Food, Drugs, Healthcare, Life Sciences

On July 29, 2026, Health Canada announced that it had obtained a permanent injunction against a Québec-based company in connection with the sale of unauthorized injectable peptides in Canada. The announcement reflects Health Canada’s continued focus on peptide products and serves as a reminder that injectable peptides intended for human use are regulated as prescription drugs and are subject to Canada's drug regulatory framework.

Health Canada appears to be administratively reclassifying Class I Medical Devices as Class II based solely on product claims rather than the established Classification Rules that focus...

Health Canada has launched a new public search portal for clinical trials authorized in Canada, alongside updated guidance documents for sponsors and applicants. The portal enhances transparency by making information about authorized clinical trials more readily accessible to patients, researchers, and industry stakeholders, while the updated guidance clarifies expectations for trial registration, summary results reporting, and public disclosure.

On July 29, 2026, Health Canada announced that it had obtained a permanent injunction against a Québec-based company in connection with the sale of unauthorized injectable peptides in Canada. The announcement reflects Health Canada’s continued focus on peptide products and serves as a reminder that injectable peptides intended for human use are regulated as prescription drugs and are subject to Canada's drug regulatory framework.

Le 24 juillet 2026, Santé Canada a publié le rapport final du Groupe de travail sur le secteur des produits pharmaceutiques et des sciences de la vie destiné à la ministre de la Santé et à la ministre de l’Industrie.

On July 24, 2026, Health Canada published the Final Report of the Pharmaceutical and Life Sciences Sector Task Force to the Ministers of Health and Industry. The Task Force was launched in March 2026 as a joint federal initiative of Health Canada and Innovation, Science and Economic Development Canada. The Task Force’s mandate was to support reliable and sustainable access to pharmaceutical products in Canada and identify made-in-Canada solutions that drive innovation, competitiveness and long-term growth in the life sciences sector.

On July 29, 2026, Health Canada announced that it had obtained a permanent injunction against a Québec-based company in connection with the sale of unauthorized injectable peptides in Canada. The announcement reflects Health Canada’s continued focus on peptide products and serves as a reminder that injectable peptides intended for human use are regulated as prescription drugs and are subject to Canada's drug regulatory framework.

Health Canada appears to be administratively reclassifying Class I Medical Devices as Class II based solely on product claims rather than the established Classification Rules that focus...

Health Canada has launched a new public search portal for clinical trials authorized in Canada, alongside updated guidance documents for sponsors and applicants. The portal enhances transparency by making information about authorized clinical trials more readily accessible to patients, researchers, and industry stakeholders, while the updated guidance clarifies expectations for trial registration, summary results reporting, and public disclosure.